← Back to all trials
Not Yet Recruiting
NCT07781709
UNDERSTANDING THE EFFECTS OF PULMONARY ARTERIAL HYPERPTENSION ON LEAN MUSCLE MASS-SUBSTUDY
Conditions: Pulmonary Arterial Hypertension
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 20
Sponsor: University of Pennsylvania
Location: University of Pennsylvania Hospital Philadelphia Pennsylvania
Summary
After completion of the Baseline study visit for the main study (MUSCLE UP-PH), participants at the University of Pennsylvania location will be invited to participate in an optional substudy. The substudy will implement a low-load resistance exercise training for the lower extremities, focusing primarily on the gastrocnemius muscles. The goal of this intervention is to understand how low-load resistance training will impact blood flow and oxygen tissue extraction on the lower legs.
Eligibility Criteria
Inclusion Criteria: Participating the main MUSCLE UP Study:
* Signed informed consent prior to initiation of any study mandated procedure.
* Male and female patient's ≥ 18 years of age.
* Diagnosis of PAH belonging to one of the following subgroups of Group 1 PH according to the updated clinical classification \[Humbert 2022\]
* Idiopathic (IPAH)
* Heritable (HPAH)
* Drugs or toxins induced
* Associated (APAH) with one of the following:
* Connective tissue disease;
* Human immunodeficiency virus (HIV) infection;
* Congenital heart disease; or
* Portopulmonary hypertension
* Diagnosis of PAH within 6 months of enrollment or diagnosis of PAH and on stable therapy for 3 months prior to enrollment
* Documented hemodynamic diagnosis of PAH by right heart catheterization (RHC), prior to enrollment showing:
* mPAP \> 20 mmHg; and
* PAWP or LVEDP ≤ 15 mmHg
* PVR \> 2 Wood units
Exclusion Criteria:
* Prior to enrollment, evidence of moderately severe obstructive ventilator defect with:
* FEV1/FVC ≤ 5th percentile; and
* FEV1 z-score \< -2.5
* Prior to enrollment, evidence of severe restrictive defect with
* TLC \< 5th percentile
* FEV1 z-score \< -4
* More than moderate aortic or mitral valve disease
* LVEF \< 40% within 1 year of screening
* Pregnancy
Source: ClinicalTrials.gov (NCT07781709). StuddyBuddy aggregates publicly available trial information.